|
| Number of RA patients (controls) | Main findings | Reference |
|
| 91 (31) | No correlation between ADMA and subendocardial viability ratio | Anyfanti et al. [94] |
| 201 | No association between ADMA and genetic variants of the AGXT2 gene | Dimitroulas et al. [95] |
| 197 | Association between microvascular function, arterial stiffness, and cIMT and ADMA/SDMA levels in RA patients with high inflammatory marker | Dimitroulas et al. [85] |
| 40 (29) | Inverse correlation between ADMA and FMD; positive correlation between ADMA and disease duration; no correlation with CRP | Sentürk et al. [88] |
| 30 (30) | No relationship between ADMA concentration and aortic augmentation; no difference in ADMA levels between patients and controls | Erre et al. [96] |
| 201 | Difference in ADMA levels according to MTHFR; positive correlation between ADMA and Hcy and ESR | Dimitroulas et al. [92] |
| 100 | No correlation between ADMA and thCys at baseline and after omega-3 fatty acids, vitamin E, vitamin A, copper, and selenium, or placebo; correlation between ADMA and arginine | Kayacelebi et al. [98] |
| 201 | Positive correlation between ADMA and ESR and ADMA and CRP | Sandoo et al. [89] |
| 33 | Correlation between ADMA and DAS28; reduction of ADMA levels after 3 months of anti-TNF | Spinelli et al. [66] |
| 201 | No significant relationship between DDAH genetic variables and ADMA levels | Dimitroulas et al. [97] |
| 17 (12) | Inverse correlation between ADMA levels and circulating EPC number | Spinelli et al. [65] |
| 35 (35) | ADMA and RF have similar sensitivity and specificity in the detection of endothelial dysfunction | Spasovski and Sotirova [91] |
| 67 | HOMA, an indicator of insulin resistance, predicts elevated ADMA levels | Dimitroulas et al. [93] |
| 48 (32) | Association between baseline PWV and ADMA but no correlation with cIMT; anti-TNF therapy increased L-arginine/ADMA ratio but not ADMA after 3 months | Angel et al. [84] |
| 20 (20) | Significantly higher ADMA levels in RA than controls; significant reduction after 12 months of treatment | Di Franco et al. [77] |
| 35 | No change in ADMA levels after 2 weeks and 3 months of anti-TNF treatment | Sandoo et al. [75] |
| 46 (50) | Higher ADMA levels in RA than in controls; correlation with CRP, DAS28, and 8-isoprostanes | Kwaśny-Krochin et al. [86] |
| 60 (29) | Significantly higher ADMA levels in RA compared with controls; no correlation with demographic or disease characteristics | Sandoo et al. [83] |
| 25 | No change in ADMA levels and cIMT after treatment | Turiel et al. [82] |
| 25 (25) | Higher ADMA levels in early RA than in controls. Significant negative correlation between ADMA levels and CFR; no correlation with IMT | Turiel et al. [90] |
| 20 | Positive correlation between ACPA and ADMA levels; no correlation with disease activity indices | Surdacki et al. [87] |
| 36 (20) | Chronic low-dose prednisolone lower ADMA levels | Radhakutty et al. [109] |
|
